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elimination of bias is a core element of high 
quality clinical trials.1 In addition to selection, 
detection, attrition, reporting and spectrum 
bias,2 a further type of bias has been reported, 
known as ‘design bias’.3 this occurs before 
the trial is begun and is inconsistent with the 
principle of ‘equipoise’ and has relevance for 
surgical trials in a different manner to the 
bias described in drug trials. equipoise is 
defined as the ‘even balance of weight or 
other forces’, or alternatively as an ‘equilib-
rium’. equipoise is an important concept in 
clinical trials, not only from an ethical stand-
point but also with regards to feasibility and 
recruitment on the part of both the clinicians 
involved and the patients who may be 
recruited. ‘clinical equipoise’ exists "if there 
is genuine uncertainty within the expert 
medical community – not necessarily on the 
part of the individual investigator – about the 
preferred treatment”.4,5
A clinician or researcher enrolling and/or 
consenting patients into a prospective ran-
domised clinical trial must believe that the 
available evidence does not indicate that the 
new treatment or intervention being studied 
is either superior or inferior to the existing 
standard treatment.6 However, an individu-
al’s equipoise can be altered by personal 
experience, anecdotal evidence or even by 
single case studies. thus the term clinical 
equipoise is used to reflect the views of the 
wider medical community, rather than the 
individual clinician. In order for patients to 
agree to participate in a clinical trial, they 
need to be well informed and understand 
there is equipoise, otherwise this will inevita-
bly result in inadequate recruitment.
The technology curve
When a new treatment is introduced whether 
it is a new drug or implant, the point of 
uncertainty within the medical community is 
not constant and fluctuates with time from 
the point of introduction. this can be com-
pared with the introduction to other new 
technologies, such as 3D printing. For these 
innovations, the uptake of these new devices 
has been described as the technology life 
cycle or ‘hype’ curve, which has five phases 
(Fig. 1).
the technology curve can be adapted to 
the uptake of medical interventions and fol-
lows the levels of evidence of research avail-
able, as well as the evolution of data for a 
given subject area. the first phase is the 
‘technology trigger’ when a new interven-
tion appears on the market and there is initial 
proof of concept data, commonly from the 
medical company or innovators bringing the 
product to market. the initial sharp rise in 
uptake of an intervention is caused by early 
adopters, followed by a growing number of 
clinicians using the technology based on 
positive data from tightly controlled case 
series, and explanatory/efficacy randomised 
trials that use strict indications for the inter-
vention, and which are often carried out by 
experts in the given area. this represents the 
second phase known as the ‘peak of inflated 
expectations’.
there is an inevitable decline in use due to 
a combination of the expansion of indica-
tions for employing the intervention in both 
case series and trials, leading to an inevitable 
rise in associated complications and poorer 
outcomes reported in the literature. this 
results in phase 3 - the ‘trough of disillusion-
ment’. these data are eventually drawn 
together in the form of systematic reviews 
and meta-analyses, and lead to the ‘slope of 
enlightenment’ (phase 4), where the indica-
tions and limitations of the intervention 
become clear. Phase 5 represents the ‘pla-
teau of productivity’ when a ‘steady state’ is 
reached, the indications for the intervention 
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are clear, and the techniques and technology involved 
has been evolved and adapted as necessary. At this stage, 
clinical equipoise is less likely to change during the 
recruitment phase, and is therefore less likely to con-
found the results of trials comparing the new interven-
tion with the current benchmark. A diverse spectrum of 
products, ranging from bone morphogenetic proteins7 
and pulsed electromagnetic fields8 to meniscal transplan-
tation9 are thought to be following this pattern.
When a system is perturbed by some agent (or data) it 
will either return to the established ‘steady state’ or settle 
at a new steady state. the path this dynamic system fol-
lows depends on how heavily ‘damped’ the system is (Fig. 
2). In relation to medical interventions, the damping of the 
system (and thus the path the system follows) will depend 
on a variety of factors including how ‘conservative’ any 
group of clinicians and patients are, the marketing of the 
product to both clinicians and patients, the simplicity of 
implementing the treatment, and the perceived and 
reported complications with which it is associated.
emerging and established technologies and treat-
ments in orthopaedic surgery can be considered to exist 
at different points along this curve. For example, emerg-
ing animal and exploratory clinical studies have raised 
expectations that mesenchymal stem cell-based thera-
pies may be used to regenerate bone and cartilage, 
although such therapies are not yet part of mainstream 
treatment.10-13 An increasing number of clinical trials 
evaluating the use of platelet rich plasma (PrP) across a 
wide range of applications have not supported promis-
ing initial in vitro and early clinical data.14-16 While a num-
ber of clinicians have become disillusioned with PrP, it is 
possible that further analysis of emerging and published 
literature may reveal particular indications in which such 
therapies are effective. these new therapies are likely to 
follow the ‘technology/hype’ curve, whereas others have 
followed a more damped pattern such as metal-on-metal 
joint arthroplasties,17,18 which has been cited as an exam-
ple of scott’s parabola.19 In some cases, such as the intro-
duction on vitamin c for preventing scurvy,20 the curve is 
even more damped (Fig. 2).
implications for clinical trials
the technology curve for a novel product reflects the 
change in perceived benefit of the clinical community 
concerning that new treatment, i.e., it reflects the clinical 
equipoise of the community. During the recruitment 
phase of a clinical trial it is desirable that clinical equipoise 
remains constant. strict inclusion and exclusion criteria 
are used to achieve this in ‘explanatory trials’, which aim 
to determine the efficacy of an intervention in ‘ideal 
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Fig. 2
graph showing the response of differently damped systems to ‘response of 
the system’. the solid line represents an undamped system, the dotted line a 
moderately damped system and the dashed line, a heavily damped system. In 
clinical practice, it has been suggested that the uptake of agents such as plate-
let rich plasma follow the solid line, whereas others such as metal-on-metal hip 
arthroplasties follow the dotted line, and vitamin c uptake the dashed line.
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Fig. 1
technology curve applied to the expectations of emerging treatments in orthopaedic surgery. the levels of evidence of research often available at each phase 
are outlined.
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conditions’21 and are, by definition, tightly controlled 
clinical trials. In contrast, pragmatic trials aim to test the 
effectiveness between an established intervention (the 
current benchmark) against the new intervention in a set-
ting most representative of day-to-day clinical practice.21 
this often results in broader inclusion/exclusion criteria, 
making the trial more prone to changes in clinical 
equipoise.
However, even in explanatory trials, a change in equi-
poise may occur, for example when new interventions 
are being initially tested and an unexpected adverse 
event rate becomes apparent on interim monitoring and 
data analysis.22 If a ‘steady state’ has been reached prior 
to carrying out a large multi-centre pragmatic trial,23 this 
will not only give equipoise, but will also inform the 
investigators which groups of patients should be 
included, thus establishing robust inclusion and exclu-
sion criteria. If an established plateau ‘steady state’ has 
not been reached at the time of commencing a pragmatic 
trial, there is a risk that the intervention being assessed 
will not be evaluated in the clinical circumstances most 
relevant to routine contemporary practice.
Therefore, to take into account the effect of chang-
ing equipoise during a clinical study, it would be ben-
eficial to monitor the uptake of the technology in a 
control group that is not in the trial. 
this will allow changes that result from the trial to be 
distinguished from changes that result from the technol-
ogy life cycle. In addition, appreciation of this curve 
allows us to introduce treatments in a manner that more 
rapidly reaches ‘plateau’. this may be by ensuring that 
treatments are optimised in a pre-clinical phase, or 
through a more concerted effort to avoid ‘widening’ 
applications of treatments without robust rationale or 
preliminary data.
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